inclusion criteria: * subject is ≥75 years old). * prior to study entry the subject was vaccinated with one of the following vaccination regimens (1st + 2nd + 3rd dose): bnt162b2 + bnt162b2 + bnt162b2 bnt162b2 + bnt162b2 + mrna-1273 mrna-1273 + mrna-1273 + mrna-1273 mrna-1273 + mrna-1273 + bnt162b2 chadox-1-s + chadox-1-s + bnt162b2 chadox-1-s + chadox-1-s + mrna-1273 the last dose of the above listed vaccinations must have been administered at least 1 month prior to study entry. vaccination status should be documented in the source data and will be captured in the ecrf. - written informed consent from subject has been obtained.

inclusion criteria: * subject is ≥75 years old). * prior to study entry the subject was vaccinated with one of the following vaccination regimens (1st + 2nd + 3rd dose): bnt162b2 + bnt162b2 + bnt162b2 bnt162b2 + bnt162b2 + mrna-1273 mrna-1273 + mrna-1273 + mrna-1273 mrna-1273 + mrna-1273 + bnt162b2 chadox-1-s + chadox-1-s + bnt162b2 chadox-1-s + chadox-1-s + mrna-1273 the last dose of the above listed vaccinations must have been administered at least 1 month prior to study entry. vaccination status should be documented in the source data and will be captured in the ecrf. - written informed consent from subject has been obtained.

inclusion criteria: subject is ≥75 years old). prior to study entry the subject was vaccinated with one of the following vaccination regimens (1st + 2nd + 3rd dose): bnt162b2 + bnt162b2 + bnt162b2 bnt162b2 + bnt162b2 + mrna-1273 mrna-1273 + mrna-1273 + mrna-1273 mrna-1273 + mrna-1273 + bnt162b2 chadox-1-s + chadox-1-s + bnt162b2 chadox-1-s + chadox-1-s + mrna-1273 the last dose of the above listed vaccinations must have been administered at least 1 month prior to study entry. vaccination status should be documented in the source data and will be captured in the ecrf. - written informed consent from subject has been obtained.

inclusion criteria: subject is ≥75 years old). prior to study entry the subject was vaccinated with one of the following vaccination regimens (1st + 2nd + 3rd dose): bnt162b2 + bnt162b2 + bnt162b2 bnt162b2 + bnt162b2 + mrna-1273 mrna-1273 + mrna-1273 + mrna-1273 mrna-1273 + mrna-1273 + bnt162b2 chadox-1-s + chadox-1-s + bnt162b2 chadox-1-s + chadox-1-s + mrna-1273 the last dose of the above listed vaccinations must have been administered at least 1 month prior to study entry. vaccination status should be documented in the source data and will be captured in the ecrf. - written informed consent from subject has been obtained.

inclusion criteria: elderly (≥75 years old) already fully vaccinated adults primary vaccination (1st and 2nd dose) using bnt162b2, mrna-1273 or chadox-1-s 9 ± 3 months since the second vaccine dose at time of enrolment for the planned 3rd vaccine dose in the trial no contra-indication against any of the vaccine products in the trial at time of enrolment genders (female, male) written informed consent from participant has been obtained

inclusion criteria: elderly (≥75 years old) already fully vaccinated adults primary vaccination (1st and 2nd dose) using bnt162b2, mrna-1273 or chadox-1-s 9 ± 3 months since the second vaccine dose at time of enrolment for the planned 3rd vaccine dose in the trial no contra-indication against any of the vaccine products in the trial at time of enrolment genders (female, male) written informed consent from participant has been obtained